

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4

In re the application of:

Toshiya KAI et al.

U.S. Serial Number: 10/534,874

Entered U.S. National Stage: May 12, 2005

International Application No. PCT/JP2003/014405

I.A. Filing Date: November 12, 2003

Confirmation No. 6777

Cust. No.: 20374

UNDER 37 C.F.R. §1.97(b)

Mail Stop PCT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

December 15, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each document is attached.

No fee or statement is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned application.

U.S. Patent Appln. S.N. 10/534,874 INFORMATION DISCLOSURE STATEMENT

PATENT

Documents UA, FB, FD and DA to DE are in the English language. Therefore, no concise explanation of the relevance of the documents under 37 C.F.R. §1.98 is believed to be required.

Documents FA and DF are not in the English language. However, the publications contain English language abstracts. The concise explanation of the relevance of the documents required under 37 C.F.R. \$1.98 is believed to be satisfied thereby.

Document FC is also not in the English language. However, the concise explanation of the relevance of the document under 37 C.F.R. \$1.98 is believed to be satisfied by the submission of an English language abstract thereof.

Documents UA, FA to FD and DA to DD have been cited in the International Search Report of the present application. A copy of the search report was submitted to the Office on May 12, 2005. Please note an Examiner's obligation to consider documents cited in an International Search Report according to the provisions of MPEP \$1893.03(g).

Please note that document DD is described in the paragraph beginning on page 1, line 8, and the paragraph beginning on page 2, line 16 of the specification of the present application. Document DE is described in the paragraph beginning on page 2, line 4. Document DF is described in the paragraph beginning on page 2, line

U.S. Patent Appln. S.N. 10/534,874 INFORMATION DISCLOSURE STATEMENT

PATENT

16.

The Commissioner is authorized to charge our Deposit Account No. 111833 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

KUBOVCIK & KUBOVCIK

Keiko Tanaka Kubovcik

Reg. No. 40,428

Atty. Case No. IWT-001 The Farragut Building Suite 710 900 17th Street, N.W. Washington, D.C. 20006

Tel: (202) 887-9023 Fax: (202) 887-9093

KTK/jbf

Attachments: PTO-1449

Eleven Documents

INFO	Atty. Docket No. IWT-001				Serial No. 10/534,874				
	Applicant: Toshiya KAI et al.								
					Filing Date: December 15, 2005				Group: Unknown
U.S. PATENT DOCUMENTS									
Examiner's Initial		Document No.	Date	١	lame	Class		Sub Class	Filing Date If appropriate
	UA	6,270,806 B1	08/07/01	Liversidge	et al.	4	424	497	
	UB								<u> </u>
FOREIGN PATENT DOCUMENTS									
Examiner's Initial	ner's Document No.		No.	Date		Country		Translation Yes/No/Partial	
	FA	01/00241 A2 0 354 855 A2 3-218309 A		01/04/01	01/04/01)	Abstract	
	FB			02/14/90		EP			
	FC			09/25/91	0/25/91			Abstract	
	FD	1 262 490 A1		12/04/02	12/04/02				
	FE								
OTHER DOCUMENTS									
Examiner's Initial									
	DA	Kamps, Jan A.A.M. et al., "Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity", <i>Biochimica et Biophysica Actai</i> , 1278 (1996) pp. 183-190.							
	DB	Panagi, Z. et al., "In vitro binding of HSA, IgG, and HDL on liposomes of different composition and its correlation with the BLOOD/RES ratio of liposomes", <i>International Journal of Pharmaceutics</i> , 176 (1999) pp. 203-207.							
	DC	Tardi, Paul G. et al., "An immune response to ovalbumin covalently coupled to liposomes is is prevented when the liposomes used contain doxorubicin", <i>Journal of Immunological Methods</i> , 210 (1997) pp. 137-148.							
	DD	Harasym, Troy O. et al., "Clearance properties of liposomes involving conjugated proteins for targeting", Advanced Drug Delivery Reviews, 32 (1998), pp. 99-118.							
	DE	Oko, Naoto et al., "Evaluation of Drug Targeting Strategies and Liposomal Trafficking", Current Pharmaceutical Design, 2000, 6, pp. 1669-1691.							
	DF	Kojima, Shuji et al., "Reduction and increase of the reticuloendotherial system (RES) uptake of glycoprotein-conjugated liposomes by linking a terminal sugar-chain with sialic acid," <i>Drug Delivery System</i> , 17-1, 2002, pp. 63-68.							
Examiner:				Da	te Consider	red:			

KTK/jbf